# Pretransplant serum IgG-anti-F(ab')<sub>2 $\gamma$ </sub> activity and kidney graft outcome: comparison of results obtained at two centers

C.Süsal<sup>1</sup>, J. Groth<sup>2</sup>, H.-H. Oberg<sup>1</sup>, P. Terness<sup>1</sup>, G. May<sup>3</sup>, G. Staehler<sup>4</sup>, and G. Opelz<sup>4</sup>

Anti-IgG autoantibodies are reported to possess immunoregulatory properties [1, 2]. In the present study, we investigated the effect of pretransplant serum IgG-anti- $F(ab')_{2\gamma}$  autoantibody activity on kidney graft outcome in recipients from two transplant centers.

**Key words:** Kidney transplantation – Autoantibodies – JgG-anti-F activity.

## Materials and methods

Pretransplant sera of 215 kidney graft recipients from Heidelberg and 474 recipients from the Berlin Friedrichshain center were tested retrospectively for IgG-anti-F(ab')<sub>2γ</sub> activity. All patients from Heidelberg and 330 patients from Berlin had a 1-year follow up. The patients were separated into those with excellent graft function (creatinine < 130 μmol/l), good graft function (creatinine 130–260 μmol/l), mediocer graft function (creatinine 260–400 μmol/l), poor graft function but no chronic dialysis (creatinine > 400 μmol/l), and graft failure. Evaluation of graft function was registered at 3, 6, and 12 months after transplantation.

For the determination of IgG-anti-F(ab')<sub>2γ</sub> activity, 96-well microtiter plates (Nunc, Roskilde) were coated at 37°C for 16 h with 0.5 μg/well of human IgG,F(ab')<sub>2</sub> fragments (Dianova, Hamburg, Germany). The plates were washed and uncoated sites were blocked with 50 µl of 1 % BAS-PBS solution at 37 °C for 3 h. We added 50 µl of 1:128 diluted test serum to the F(ab')<sub>2y</sub>-coated wells. PBS-Tween 0.05% was used as washing buffer and p-nitro-phenyl phosphate disodium solution (Sigma, St. Louis, Mo.) as substrate. Incubation steps with sera or antibodies were performed at 22°C for 1 h. After each step the plates were washed four times with washing buffer. The reaction was developed with 50 µl of an alkaline phosphatase-conjugated goat antibody specific for IgG,Fc (Dianova, working dilution 1:5000). The results are expressed as mean optical density (OD) ± SEM read at 405 nm using an MR 700 Microplate Reader (Dynatech, ChantillY, Va.). Statistical analysis was performed using the rank-sum test of Wilcoxon.

#### Results

The results were concordant at the two centers. A significant association was found between pretransplant IgGanti-F(ab')<sub>2y</sub> activity and 3-month (Table 1) and 1-year (Table 2) kidney graft outcome. When all patients were analyzed, IgG-anti-F(ab')<sub>2</sub>, activity in pretransplant sera of recipients with graft failure or poor graft function (creatinine > 400 µmol/l) at 3 month was significantly lower than the activity in recipients with a 3-month serum creatinine of  $< 130 \,\mu\text{mol/l}$  (P = 0.0085). A particularly high IgG-anti-F(ab')<sub>27</sub> activity was found in patients with immediately functioning grafts and a 3-month creatinine of  $< 130 \,\mu\text{mol/l}$  (P < 0.0001, as compared to patients with graft failure or poor graft function). Patients with 3-month creatinines of 130-260 µmol/l or 260-400 µmol/l had intermediate IgG-anti-F(ab')27 activities (compared to patients with immediately functioning grafts and creatinine

Table 1. Pretransplant IgG-anti-F(ab') $_{2\gamma}$  activity and early 3-month graft function

Recipients from the Heidelberg and Berlin Friedrichshain transplant centers were separated into groups according to their 3-month serum creatinines. The highest IgG-anti-F(ab')<sub>2 $\gamma$ </sub> activity (mean  $\pm$  SEM) was found in patients with immediately functioning grafts and a 3-month serum creatinine of < 130  $\mu$ mol/l

Serum creatinine (µmol/l)	IgG-anti-F(ab') <sub>2γ</sub> Serum activity		
	Heidelberg	Berlin	All patients
<130 and immediate function	$1297 \pm 102$ n = 64	$1390 \pm 78$ $n = 81$	$1330 \pm 62$ $n = 145$
< 130	$1152 \pm 65$ $n = 141$	$1175 \pm 51$ $n = 162$	$1168 \pm 40*$ $n = 303$
130–260	$1197 \pm 181$ $n = 31$	$1032 \pm 46$ $n = 201$	$1063 \pm 48$ $n = 232$
260–400	$738 \pm 208$ $n = 7$	$1046 \pm 94$ $n = 35$	$991 \pm 86$ $n = 42$
> 400 or graft failure	$934 \pm 106$ $n = 36$	$1014 \pm 81$ $n = 76$	$987 \pm 65*$ $n = 112$

<sup>\*</sup> Excellent graft function versus poor graft function or graft failure, P = 0.0085

<sup>&</sup>lt;sup>1</sup> Department of Transplantation Immunology, Institute of Immunology, University of Heidelberg, Im Neuenheimer Feld 305, D-6900 Heidelberg, Germany

<sup>&</sup>lt;sup>2</sup> Department of Experimental Organ Transplantation, Humboldt University School of Medizin, Berlin, Germany

<sup>&</sup>lt;sup>3</sup> Department of Urology, Friedrichshain Hospital, Berlin, Germany

<sup>&</sup>lt;sup>4</sup> Department of Urology, Surgical Clinic, University of Heidelberg, Heidelberg, Germany

Table 2. Pretransplant IgG-anti-F(ab')<sub>2γ</sub> activity and 1-year kidney graft outcome

Recipients from the Heidelberg and Berlin Friedrichshain centers were separated into groups according to their 1-year serum creatinine levels. The highest IgG-anti-F(ab')<sub>2γ</sub> activity (mean  $\pm$  SEM) was found in patients with immediately functioning grafts and a 1-year serum creatinine of < 130  $\mu$ mol/l

-	·			
Serum creatinine (µmol/l)	IgG-anti-F(ab') <sub>2</sub> γ Serum activity			
	Heidelberg	Berlin	All patients	
< 130 and immediate function	$1271 \pm 108$ n = 60	$1350 \pm 89$ $n = 44$	$1310 \pm 72$ $n = 104$	
< 130	$1166 \pm 70$ $n = 123$	$1145 \pm 60$ $n = 104$	$1157 \pm 47*$ $n = 227$	
130–260	$1146 \pm 174$ $n = 31$	$986 \pm 51$ $n = 112$	$1018 \pm 55$ $n = 143$	
260–400	$971 \pm 245$ $n = 8$	$967 \pm 99$ $n = 26$	$971 \pm 93$ $n = 34$	
> 400 or graft failure	$886 \pm 98$ $n = 48$	$971 \pm 74$ $n = 88$	$934 \pm 58*$ $n = 136$	

<sup>\*</sup> Excellent graft function versus poor graft function or graft failure, P = 0.0009

 $< 130 \mu mol/l$  at 1 year: P = 0.0001 and 0.0012, respectively) (Table 1).

The association between IgG-anti-F(ab')<sub>2 $\gamma$ </sub> activity and kidney graft outcome was evident even more clearly at 1 year. As shown in Table 2, a high IgG-anti-F(ab')<sub>2 $\gamma$ </sub> activity was found in recipients who had a serum creatinine of <130 µmol/l at 1 year. The IgG-anti-F(ab')<sub>2 $\gamma$ </sub> activity in patients with immediately functioning grafts and a 1-year creatinine of <130 µmol/l was significantly higher than that in recipients with a creatinine of 130–260 µmol/l, 260–400 µmol/l, or in recipients with graft failure or poor function (creatinine >400 µmol/l) at 1 year (P<0.0003, 0.0051, and P<0.0001, respectively).

## Discussion

The results described here are an extension of our previous finding that anti- $F(ab')_{2\gamma}$  antibodies of athe IgG isotype are associated with good kidney graft outcome [3], both with respect to early and 1-year graft function. The results were in agreement with data published by Chia et

al. [4], however, they did not agree with a recent study published by the same group in which they could not confirm their previous finding [5].

The protective effect of IgG-anti-F(ab')<sub>2 $\gamma$ </sub> antibodies on graft survival may be due to their antiidiotypic activity as suggested by Nasu et al. [6], or to negative Fc $_{\gamma}$  signaling induced by IgG-immune complexes [7, 8]. It is unknown whether the antigenic sequence recognized by IgG-anti-F(ab')<sub>2 $\gamma$ </sub> is in the constant or variable region of IgG. Evidence exists for both alternatives [6, 9]. We believe that anti-immunoglobulin antibodies of different isotypes and different specificities with diverse and even counteracting effects exist.

Acknowledgements. We wish to acknowledge the excellent technical assistance of Cima Farahmandi, Sibylle Braun, and Angela Edelmann. This work was supported by a grant from the Transplantationszentrum Heidelberg.

# References

- 1. Parker DC (1980) Induction and suppression of polyclonal antibody responses by anti-Ig reagents and antigen-nonspecific helper factors: a comparison of the effects of anti-Fab, anti-IgM, and anti-IgD on murine B cells. Immunol Rev 52: 115–139
- Terness P, Süsal C, Baur C, Opelz G (1990) A B-cell suppressive IgG-anti-immunoglobulin antibody induced by alloimmunization. Transplantation 50: 502–505
- 3. Süsal C, Guo Z, Terness P, Opelz G (1990) Role of anti-IgG autoantibodies in kidney transplantation. Immunol Lett 26: 121–125
- Chia D, Horimi T, Terasaki PI, Hermes M (1982) Association of anti-Fab and anti-IgG antibodies with high kidney transplant survival. Transplant Proc 14: 322–324
- 5. Feduska NJ Jr, Chia D, Terasaki PI, Sugich L (1991) Effect of anti-Fab antibodies on renal allografts. Transplant Proc 23: 1277–1278
- Nasu H, Chia DS, Knutson DW, Barnett EV (1980) Naturally occuring human antibodies to the F(ab')<sub>2</sub> portion of IgG. Clin Exp Immunol 42: 378–386
- Bijsterbosch MK, Klaus GGB (1985) Crosslinking of surface immunoglobulin and Fc receptors on B lymphocytes inhibits stimulation of inositol phospholipid breakdown via the antigen receptors. J Exp Med 162: 1825–1836
- Uher F, Lamers MC, Dickler HB (1985) Antigen-antibody complexes bound to B-lymphocyte Fc
   receptors regulate B-lymphocyte differentiation. Cell Immunol 95: 368–379
- 9. Wolfe LD, Abruzzo JL, Heimer R (1984) Specificity of IgM antibodies to pooled human F(ab')<sub>2</sub> fragments. Immunol Commun 13: 15–27